|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | ||||||
| Short term deposit | ||||||
| Restricted cash | ||||||
| Prepaid clinical trial expenses and deferred clinical trial costs | ||||||
| Short-term deposits | ||||||
| Prepaid expenses and other current assets | ||||||
| Total current assets | ||||||
| Non-current assets | ||||||
| Intangible assets, net | ||||||
| Goodwill | ||||||
| Operating lease right of use asset | ||||||
| Property and equipment, net | ||||||
| Total non-current assets | ||||||
| Total assets | ||||||
| Liabilities and shareholders’ equity | ||||||
| Current liabilities: | ||||||
| Trade payables | ||||||
| Employees and related liabilities | ||||||
| Operating lease liability | ||||||
| Accrued expenses | ||||||
| Total current liabilities | ||||||
| Non-current liabilities: | ||||||
| Operating lease liability | ||||||
| Provision for unrecognized tax positions | ||||||
| Total non-current liabilities | ||||||
| Total liabilities | ||||||
| Shareholders’ Equity: | ||||||
| Ordinary shares, No par value; Authorized: 12,000,000 and 500,000 shares as of December 31, 2025, and 2024, respectively; Issued and outstanding: 830,613 and 341,827 shares as of December 31, 2025, and 2024, respectively | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total equity attributable to shareholders of the Company | ||||||
| Non-controlling interests | ||||||
| Equity, Including Portion Attributable to Noncontrolling Interest, Total | ||||||
| Total liabilities and equity | ||||||
Loading...
